Briefing documents released ahead of a May 10 advisory panel meeting are confirming investor fears that safety signals may block Ionis Pharmaceuticals and Akcea Therapeutics' volanesorsen from market, or at least seriously impair the drug if it gets there.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,